Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Spriano

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Cancers|June 26, 2025
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell LymphomasChiara Tarantelli, Filippo Spriano, Elisa Civanelli, et al.
British Journal of Haematology|July 30, 2019
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomasFilippo Spriano, Chiara Tarantelli, Eugenio Gaudio, et al.
British Journal of Haematology|December 9, 2025
A high-throughput bone marrow 3D co-culture system to study resistance to BCR signalling targeted agents in B-NHLAlex Zadro, Alberto Arribas, Maria Vittoria Colombo, et al.
British Journal of Haematology|July 31, 2024
Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agentsFilippo Spriano, Chiara Tarantelli, Luciano Cascione, et al.
Ejhaem|September 2, 2022
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphomaFilippo Spriano, Giulio Sartori, Chiara Tarantelli, et al.
European Journal of Medicinal Chemistry|August 11, 2019
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell linesAnna Lucia Fallacara, Raffaele Passannanti, Mattia Mori, et al.
Cancers|June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxChiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
Blood Advances|May 17, 2021
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitorsAfua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, et al.
British Journal of Haematology|June 28, 2017
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphomaElena Bernasconi, Eugenio Gaudio, Pascale Lejeune, et al.
Haematologica|June 24, 2021
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphomaSara Napoli, Luciano Cascione, Andrea Rinaldi, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Cancers|June 26, 2025
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell LymphomasChiara Tarantelli, Filippo Spriano, Elisa Civanelli, et al.
British Journal of Haematology|July 30, 2019
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomasFilippo Spriano, Chiara Tarantelli, Eugenio Gaudio, et al.
British Journal of Haematology|December 9, 2025
A high-throughput bone marrow 3D co-culture system to study resistance to BCR signalling targeted agents in B-NHLAlex Zadro, Alberto Arribas, Maria Vittoria Colombo, et al.
British Journal of Haematology|July 31, 2024
Targeting CD25+ lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agentsFilippo Spriano, Chiara Tarantelli, Luciano Cascione, et al.
Ejhaem|September 2, 2022
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphomaFilippo Spriano, Giulio Sartori, Chiara Tarantelli, et al.
European Journal of Medicinal Chemistry|August 11, 2019
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell linesAnna Lucia Fallacara, Raffaele Passannanti, Mattia Mori, et al.
Cancers|June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxChiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
Blood Advances|May 17, 2021
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitorsAfua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, et al.
British Journal of Haematology|June 28, 2017
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphomaElena Bernasconi, Eugenio Gaudio, Pascale Lejeune, et al.
Haematologica|June 24, 2021
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B-cell lymphomaSara Napoli, Luciano Cascione, Andrea Rinaldi, et al.
Pageof 4